A two staged treatment procedure for the difficult to treat bladder neck contractures with concomitant incontinence. In the search of a solution to a complex problem

Ioannis Adamakis, Evangelos Fragkiadis, Ioannis Katafigiotis, Giorgos Kousournas, Konstantinos Stravodimos, Constantinos A. Constantinides

1st University Urology Clinic, Laiko Hospital, Greece.

Summary

Objective: To examine the efficacy of a two staged treating strategy with the use of a non-permanent urethral ALLIUM® stent for the management of recurrent bladder neck stenosis and subsequently the use of an artificial sphincter AUS800® by AMS for the management of the incontinence.

Materials and Methods: We progressively identified patients eligible for the study creating a population of cases with recurrent bladder neck stenosis and concomitant incontinence occurring after the last intervention for the stenosis. Efficacy for the treatment of the stenosis was defined as no recurrence both prior and post to the sphincter placement and efficacy for the treatment of the incontinence was defined as continence (0-1 pads) after the sphincter placement.

Results and Limitations: 14 white males with a mean age of 66.21, ranging from 59 to 73 years consisted the population of the study. All patients had severe stress incontinence following the last transurethral resection. The efficacy of the treatment of the bladder neck stenosis was 93% (13/14) while the efficacy for the treatment of the incontinence was 100%. A single patient had a recurrent bladder neck stenosis after the artificial sphincter placement and was treated with transurethral resection using a long pediatric 13 F resectoscope at 12 months. Our limitations is the absence of a control group and the small number of patients enrolled, with a relatively short time of follow up.

Conclusions: In our series we propose the use of a non-permanent urethral ALLIUM® stent for 6 months in order to control the growth of fibrotic scar tissue, a further 6 months follow up for recurrence, and then placement of an artificial sphincter. The results are very promising both on stabilizing the vesicourethral stenosis, and on patient safety and tolerability.

Key words: Vesicourethral anastomosis stenosis; Bladder neck contracture; Urethral stent.

Submitted 10 March 2015; Accepted 30 April 2015

Introduction

Vesicourethral anastomosis stenosis and bladder neck contracture is a deferred complication of prostate surgery; predominantly in radical prostatectomy, that occurs in 0.5% to 14.6% of the patients (1). A number of risk factors have been clearly described: age, increased Body Mass Index, previous prostate surgeries, open surgical technique, postoperative haematuria, urinary leak and urinary retention, external beam radiation and biochemical recurrence (2, 3). The vast majority of anastomotic strictures manifest within the first year post operatively (4).

Different management approaches have been proposed according to the severity of each case, such as dilation, laser or cold cut incisions, use of corticosteroids, transurethral resection of fibrotic tissue, revision surgery and urinary diversion surgery. No consensus has been reached in their management and, despite the use of different and combined techniques, the need for repeat treatment remains as high as 70% depending on the method (5). In the more severe and relapsing cases, patients end up incontinent after multiple treatments, while obstruction is refractory to usual endoscopic modalities. It is evident that bladder neck contractures cause seriously morbidity and affect the quality of life of patients while the cost rises due to multiple procedures.

We present the results of our prospective study of a new treatment modality for patients with severe symptoms caused by bladder neck obstruction, recalcitrant to multiple and different endoscopy treatment modalities. All patients had developed severe stress incontinence after previous endoscopic treatments for bladder neck obstruction. Patients were treated with the placement of a non-permanent urethral ALLIUM® stent (6) for 6 months in order to control the growth of fibrotic scar tissue. After that the stent was removed and the patients were further followed up for 6 months and if remained unobstructed an artificial sphincter was placed to treat incontinence.

Materials and methods

Patient characteristics are depicted in Table 1. Fourteen white males with a mean age of 66.21, ranging from 59 to 73 years consisted the population of the study. Ten patients were subjected to open radical prostatectomy as primary surgery, 1 patient to radical cystectomy and orthotopic neobladder, 2 patients to open transvesical adenomectomy and 1 patient to transurethral prostatectomy.

Patient inclusion criteria were recurrent bladder neck
obstructions after at least 2 transurethral resections of fibrotic tissue post primary surgery, as well as multiple treatment modalities such as laser incision and use of corticosteroids. All patients had severe stress incontinence following the last transurethral resection.

In all patients with a history of prostate and bladder cancer, a relapse was excluded through digital rectum examination (DRE), prostatic specific antigen (PSA) and pathology report of the transurethral resection. The clinical study was approved by the scientific committee of our hospital and all the patients signed a written consent after a detailed presentation of our treatment approach.

The primary objective was to examine the efficacy in the treatment of the recurrent urethral contracture after the placement of the sphincter in the 12 month follow up.

The secondary objective was to examine the efficacy of the treatment of the severe stress incontinence induced over multiple recurrences and treatments after the placement of the sphincter in the 12 month follow-up. All complications were recorded after patient evaluation and clinical examination and classified according to the Clavien-Dindo Score (Table 3).

Patients were treated by a single surgeon with an aggressive transurethral resection of obstructive fibrotic tissue. Placement of the ALLIUM® stent was facilitated under sedation and fluorescence control for proper placement and stent measurement after 1 week. Figure 1. The stent was removed after 6 months, and patients were followed up for stenosis recurrence at 1, 3 and 6 months with post voiding residual ultrasound and at 6 months with urethrography. If patients were unobstructed at 6 months, an artificial sphincter AUS800® by AMS was placed with open perineal surgery and patients were again followed up at 1, 3, 6 and 12 months (mean follow up time 12.93 months). Treatment scheme is reported in Figure 2.

The ALLIUM® stent is a 45 F triangular polyester coated stent designed for high flexibility, low irritation, long indwelling time, reduced migration due to trans-papillary anchor, acting as a wide mold to the development of scar tissue and allowing for time of fibrotic tissue to stabilise. ALLIUM® stent is provided in 45 mm and 55 mm length.

Table 1.
Patient’s clinical details.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>14 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>14 patients</td>
</tr>
<tr>
<td>Patient age</td>
<td>66.21</td>
</tr>
<tr>
<td>59-73 age range</td>
<td></td>
</tr>
<tr>
<td>Primary surgery</td>
<td>10 open RRP</td>
</tr>
<tr>
<td>1 open RC</td>
<td>2 open TVA</td>
</tr>
<tr>
<td>1TUR +</td>
<td></td>
</tr>
<tr>
<td>Number of transurethral resections prior to trial enrollment</td>
<td>3.64</td>
</tr>
<tr>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Patients with other treatments applied</td>
<td>3 laser incisions</td>
</tr>
<tr>
<td>3 application of corticosteroids</td>
<td>14 patients</td>
</tr>
<tr>
<td>Severe incontinence</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>PSA prior to enrollment</td>
<td></td>
</tr>
</tbody>
</table>

Table 2.
Results.

<table>
<thead>
<tr>
<th>Results</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days after resection for stent placement</td>
<td>6.25</td>
</tr>
<tr>
<td>Months of indwelling stent</td>
<td>6.7</td>
</tr>
<tr>
<td>Follow up after stent removal and time of sphincter placement</td>
<td>6.14</td>
</tr>
<tr>
<td>Bladder neck stenosis at sphincter placement</td>
<td>6.4-6.5</td>
</tr>
<tr>
<td>Follow up after sphincter placement</td>
<td>0/14</td>
</tr>
<tr>
<td>Continence achieved (0-1 pad per day)</td>
<td>12/13</td>
</tr>
<tr>
<td>Recurrence of bladder neck stenosis</td>
<td>14/14</td>
</tr>
<tr>
<td>Transurethral resection</td>
<td>Self reported at 12 months</td>
</tr>
</tbody>
</table>

Table 3.
Complications.

<table>
<thead>
<tr>
<th>Complications</th>
<th>No of patients</th>
<th>Intervention</th>
<th>Clavien score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stent migration</td>
<td>1/14 after 1 month</td>
<td>Replacement</td>
<td>3.1</td>
</tr>
<tr>
<td>Acute urinary retention</td>
<td>1/14 immediately</td>
<td>Suprapubic urine drainage &amp; NSAID</td>
<td>3.1</td>
</tr>
<tr>
<td>Perineal pain</td>
<td>2/14</td>
<td>Paracetamol</td>
<td>1</td>
</tr>
<tr>
<td>Dysuria</td>
<td>8/14</td>
<td>Self resolved</td>
<td>1</td>
</tr>
</tbody>
</table>

RESULTS

All 14 patients remained unobstructed for the complete time of follow up prior to sphincter placement, after the removal of the ALLIUM® stent. A single patient has relapsed after the artificial sphincter placement and was treated with transurethral resection using a long pediatric 13 F resectoscope at 12 months and as a result the
final efficacy was 93%. All 14 patients regained full continence after the application of the sphincter using 0-1 light pad per day (Efficacy 100%). Patients results are reported in Table 2. In 1 patient, acute urinary retention occurred immediately after the stent placement, resolved by the use of suprapubic urine drainage and NSAIDs for one week, then suprapubic drainage was removed and patient was unobstructed. One case of stent migration at 1 month was reported with successful replacement of the stent. The stent was well tolerated with mild dysuria complaints in 8 cases, 2 patients further reported perineal pain, well controlled with paracetamol. All patients had no dysuria or pain after stent removal. Complications are reported in Table 3.

**DISCUSSION**

Treatment of vesicourethral anastomosis stenosis is very challenging, due to the heterogeneity of the patients requiring different therapeutic approaches. Furthermore the high relapse rates affect significantly patient's quality of life adding both to the morbidity and the cost due to the demand for multiple operations.

For cases with minimal fibrotic tissue the initial approach usually is the transurethral dilating balloon with success rates of 59%, but with recurrence rates of 70% with the occurrence of dense scar tissue as the cause of treatment failures (5). Use of cold knife incision has also been suggested as the initial approach of strictures in continent patients, with good continence clinical results similar to patients with no strictures after radical prostatectomy in a 18.9 months follow up (7). Giannarini et al., investigated the efficacy of balloon dilation compared to multiple cold cut incision over an extended follow up of 48 months, establishing the superiority of the cold cut approach, but also the frequent need of re-treatment (26%), the preservation of continence in all patients and the improvement of incontinence prior to treatment (4).

In an attempt to improve long term results multiple treatment options have been proposed. The cold knife incision has been combined with the in situ injection of mitomycin C, reaching an 89% success rate, but still requiring multiple treatments (8).

More complicated cases with contractures due to dense fibrotic tissue without sphincter involvement and without stress incontinence are usually treated with the facilitation of cautery incision and resection or laser. The use of the transurethral resection of bladder neck contractures has been proven safe when the obstruction was located below the bladder neck musculature, well above the distal urethral sphincter (9). Comparing the resection of the stricture with a bipolar endoscopic resection and Holmium laser treatment similar success results has been reported, but more durable in the case of bipolar use, with the same complication rates regarding continence (10). In the same principal, plasma vaporisation has been compared with transurethral resection in bladder neck sclerosis, post monopolar transurethral resection, with bipolar modality showing superior efficacy, a satisfactory safety profile in similar medium-term follow-up (11). Collins knife incision has also been used in neurovesical strictures over transurethral resection, but with the assistance of continuous intermittent catheterisation to preserve the results (12). The previous studies treated patients with mild obstruction and with none or mild to moderate incontinence, hence different than our group, which consisted of patients with severe obstruction and severe incontinence.

An even more difficult to treat subset of patients have bladder neck contractures that involve the sphincter causing stress incontinence, that are due to previous endoscopic treatments affecting the sphincter so adding incontinence to the symptoms along with recurrence. A bladder neck incision technique with a Collins knife electrocautery has been used for the treatment of these more challenging cases, as part of a two staged procedure dealing with the bladder neck contracture first, and at a deferred stage with the incontinence, but still with a high recurrence rate of 25% (13). The use of Holmium laser incision with the adjuvant use of triamcinolone has been proposed for incontinence patients relapsing after previous treatment, with placement of the artificial sphincter as early as 2 months, but with a high retreatment rate of almost 29% (14).

In patients refractory to endoscopic approach, more invasive solutions such as perineal reconstructive surgery or placement of urethral stents has been suggested (15). In similar populations with complicated strictures or contractures, but with concomitant incontinence, a two staged management of open reconstructive surgery and artificial sphincter placement seems to be the primary...
choice (16). In order to avoid the copious reconstructive perineal surgery Magera et al. opted for multiple stent placement and implantation of an artificial sphincter, achieving success rates of 76% (17). Elliot et al. with the same approach and the use of a permanent stent, reported a success rate 89% with mild pain symptoms (18). This more complex patient subset with a history of multiple endoscopic treatments, high recurrence rate and severe stress incontinence, trapped in a vicious cycle of incontinence to retention and back, is closer to our case series.

Breyer et al. in an excellent review on the management of refractory bladder neck contractures after radical prostatectomy, summarised the shortcomings of stents (19). Stents, being a foreign body, carry a lifelong infection risk. Stent placement can induce urinary urgency, frequency or dysuria if it is near the trigone, and if it is placed too distally, perineal discomfort may occur in a sitting position. A restenosis of the stent may occur, due to either recurrent scar tissue or to calculi, requiring endoscopic excision. When stenosis recurs after the placement of the artificial sphincter the repeated endoscopic interventions may harm the artificial urinary sphincter (AUS). Finally, once placed, the stent is extremely difficult to remove, requiring an open surgical approach. Most of these disadvantages are intrinsic to the permanent nature of stents, thus using a non permanent stent such as ALLIUM® stent we possibly can circumvent them.

The two stage treatment seems to be well established in patients with severe anastomotic strictures and severe incontinence. The primary step of this two stage treatment is to establish a stable, open vesicourethral anastomosis and, in most cases, specialised perineal reconstructive surgery is being utilised. The use of permanent stents to replace complex open surgery is an intriguing possibility, with proven similar efficacy to reconstructive surgery. On the other hand the utilisation of a permanent stent has some disadvantages, inherent to the use of a foreign body including urgency, frequency, dysuria, pain, infection, and in some cases restenosis. The two stage treatment always facilitates placement of an artificial sphincter to successfully treat incontinence.

In our series we propose the use of a non-permanent urethral ALLIUM® stent for 6 months in order to control growth of fibrotic scar tissue, and, after a further 6 months follow up for recurrence, placement of an artificial sphincter. The results are very promising in order to stabilize the vesicourethral stenosis with patient safety and tolerability and the procedure is easy to apply in a standard facility setting. Most important is the fact that no stent is left indwelling after the first 6 months, thus bypassing most of the disadvantages mentioned in relation to permanent stents (i.e. risk of infection, pain, discomfort, difficulty of endoscopic procedures and removal) without compromising recurrent stenosis or successful long lasting results. As our series demonstrate, all 14 patients remained stable and unobstructed in the 6 month follow up period and the single recurrence 9 months after sphincter placement was readily resolved with a transurethral resection, thus 13/14 patients were recurrence free for the complete follow up period. All 14 patients regained continence after the application of the artificial sphincter.

Our limitations is the absence of a control group and the small number of patients enrolled, with a relatively short time of follow up. Although this is an initial case series study, of a very complicated difficult to treat group of patients, with extended stenosis, multiple recurrence and severe incontinence, the follow up scheme is strict and comparable to similar studies. Due to the solid promising results of our novel treatment modality it should be considered as a candidate to add to the armament of the urologist in treating complex cases of vesicourethral contractures. A comparative randomised clinical trial with a larger patient sample and longer follow up is definitely needed to establish the right method for the right patient.

REFERENCES


Correspondence
Ioannis Adamakis, MD Assistant Professor
yiannon@hotmail.com

Evangelos Fragkidas, MD Urologist - Scientific Associate
e.fragkidas@gmail.com

Giorgos Kousouras, MD Resident
giorgoskousouras@gmail.com

Konstantinos Stratodimos, MD Associate Professor
kgstravod@yahoo.com

Constantinos A. Constantinides, MD Professor of Urology
ckonstantin@med.uoa.gr

Ioannis Katafigiotis MD,MLS,PhD (Corresponding Author) Resident
katafigiotis@yahoo.com

Department of Urology, Athens University Medical School, Greece
Laiko Hospital
17 Agiou Thoma str., 11527, Athens, Greece